Mostrar el registro sencillo

dc.contributor.authorEncinas, Cristinaes_ES
dc.contributor.authorHernández Rivas, José Ángeles_ES
dc.contributor.authorOriol, Albertoes_ES
dc.contributor.authorRisoñol, Lauraes_ES
dc.contributor.authorBalchard, María Jesúses_ES
dc.contributor.authorBellón, José Maríaes_ES
dc.contributor.authorGarcía Sanz, Ramónes_ES
dc.contributor.authorRubia, Javier de laes_ES
dc.contributor.authorLópez de la Guía, Anaes_ES
dc.contributor.authorJimenez Ubieto, Anaes_ES
dc.contributor.authorJarque, Isidroes_ES
dc.contributor.authorIñigo, Belénes_ES
dc.contributor.authorDourdil, Victoriaes_ES
dc.contributor.authorArriba, Felipe dees_ES
dc.contributor.authorCuéllar Pérez-Ávila, Claraes_ES
dc.contributor.authorGonzalez, Yolandaes_ES
dc.contributor.authorHernández, Miguel Teodoroes_ES
dc.contributor.authorBargay, Joanes_ES
dc.contributor.authorOcio San Miguel, Enrique María es_ES
dc.contributor.authorGranell, Migueles_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2023-03-21T08:58:19Z
dc.date.available2023-03-21T08:58:19Z
dc.date.issued2022es_ES
dc.identifier.issn2044-5385es_ES
dc.identifier.urihttps://hdl.handle.net/10902/28285
dc.description.abstractInfections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ?30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0?2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.es_ES
dc.description.sponsorshipAcknowledgements: The authors thank Arturo Touchard and Roberto Maldonado for their help with data management and Kenneth McCreath for manuscript editing. The present study was sponsored by PETHEMA (Spanish Program for the Treatment of Hematological Diseases), Madrid, Spain, and was coordinated by the Spanish Myeloma Group (GEMPETHEMA; chair, Juan-José Lahuerta). The contents are solely the responsibility of the authors.es_ES
dc.format.extent8 p.es_ES
dc.language.isoenges_ES
dc.publisherNature Pub. Groupes_ES
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceBlood Cancer Journal (2022) 12:68es_ES
dc.titleA simple score to predict early severe infections in patients with newly diagnosed multiple myelomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1038/s41408-022-00652-2es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1038/s41408-022-00652-2es_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International